PCI Biotech CCA study selected for presentation

Oslo: October 17, 2016 – PCI Biotech, the cancer focused biopharmaceutical company, announced that an abstract with results from their Phase I cholangiocarcinoma study had been selected for oral presentation as late-breaking news at this week’s United European Gastroenterology (UEG) conference in Vienna, Austria.

The results will be presented by Dr. Alexander Dechêne, University Hospital Essen, Germany, who is one of the investigators in the Phase I study.

To see Dr Dechêne’s presentation “Phase I study with photochemical Internalisation (PCI) – a novel technology for treatment of perihilar cholangiocarcinoma“ click here

Although this international study (Germany, Norway and the UK) was small, the reseachers have seen a response rate far above expected results with standard treatment (Gemcitabine/Cisplatin chemotherapy). They are very encouraged by these early indicators of efficacy using PCI treatment with fimaporfin and gemcitabine.

PCI Biotech are now looking to take this study to the next stage of development.

To read more information from PCI Biotech on  this study, click here

(AMMF is pleased to be part of PCI Biotech’s consortium going forward for the Phase II trial)

 

October 2016

Bookmark and Share